84.4% of cancer patients taking ivermectin declared COMPLETE REMISSION, TUMOR SHRINKAGE, or HALTED TUMOR GROWTH
The LARGEST human ivermectin cancer study EVER conducted is now PEER-REVIEWED and PUBLISHED by the International Institute of Anticancer Research.
We are WINNING.
BREAKING: Largest Human Cancer Study of Ivermectin + Mebendazole Is Now PEER-REVIEWED and PUBLISHED in a MAJOR Cancer Journal
84.4% of cancer patients taking ivermectin + mebendazole for 6 months declared either CANCER DISAPPEARANCE, TUMOR REGRESSION, or CANCER STABILIZATION.
Our study, “Real-world Clinical Outcomes of Ivermectin and Mebendazole in Cancer Patients: Results from a Prospective Observational Cohort,” is now peer-reviewed and published in Anticancer Research—a major international oncology journal of the International Institute of Anticancer Research (IIAR), established in 1995.
The results represent one of the most compelling clinical signals ever documented for repurposed anti-parasitic therapies in oncology.
A diverse population of cancer patients (n=197) was prescribed compounded ivermectin–mebendazole through a U.S. telemedicine platform, with each capsule containing 25 mg ivermectin and 250 mg mebendazole.
Participants were followed for approximately six months using standardized digital surveys assessing cancer outcomes, medication adherence, and tolerability.
At approximately six months post-treatment initiation, we observed an 84.4% Clinical Benefit Ratio (CBR)—meaning more than four out of five patients reported either:
No evidence of disease (32.8%)
Tumor regression (15.6%)
or Cancer stabilization (36.1%)
Importantly, adherence was remarkably high, with 86.9% completing the initial prescription and 66.4% remaining on therapy at six months.
Side effects were predominantly mild and manageable, reported in 25.4% of patients (primarily gastrointestinal), with 93.6% of those experiencing side effects continuing treatment after minor dosing adjustments.
This groundbreaking peer-reviewed publication was made possible through a unique collaboration between The Wellness Company, the McCullough Foundation, and the Chairman of the President’s Cancer Panel—uniting real-world clinical data, frontline medical experience, and epidemiologic expertise to evaluate inexpensive, repurposed therapies with major translational potential.
With these extraordinarily promising results, double-blind, placebo-controlled clinical trials are now required.
In the meantime, many cancer patients are exercising their right to try.
@twc_health@McCulloughFund@IIAR_Journals@P_McCulloughMD@DrHarveyRisch@DrKellyVictory@jathorpmfm@drdrew@PeterGillooly@FosterCoulson
Here’s @RealCandaceO back in 2018 talking to Joe Rogan about how brilliant Charlie Kirk is and how she believes he could be a future president of the United States.
“In my opinion, he’s going to be a future president of the United States. Everyone [who meets him] says that.”
This was the finest and most consequential political speech of my lifetime. It was what Americans needed to hear. JD Vance earned my vote. Thank you JD.
Justice for Charlie is coming.
I thought about clipping this but honestly? It's the most consequential speech of our time and you all need to watch it in full.
Once again, a bullet has silenced the most eloquent truth teller of an era. My dear friend Charlie Kirk was our country's relentless and courageous crusader for free speech. We pray for Erika and the children. Charlie is already in paradise with the angels. We ask his prayers for our country.
The Federal Reserve's preferred inflation metric, Core PCE, rose by 0.3% in January compared to the previous month, meeting expectations. On an annual basis, Core PCE slowed to 2.6%, nearing the lowest rate observed in four years. #pce#inflation#mortgagemarketnews